Τομέας Βασικών ΕπιστημώνLibrary of the School of Health Sciences
Καθηγητής Ιστολογίας Εμβρυολογίας Χρήστος Κίττας, Καθηγητής Ανατομικής Ιστολογίας Εμβρυολογίας Ευάγγελος Μανώλης, Αναπληρωτής Καθηγητής Παθολογικής Ανατομικής Σταμάτιος Θεοχάρης.
Η σημασία της έκφρασης του RCAS1 στον καρκίνο του πνεύμονα.
The significance of RCAS1's expression in lung cancer.
Introduction: Lung cancer is an important health problem worldwide due to its
incidence and mortality. RCAS1 (Receptor-binding Cancer Antigen expressed on
SiSo cells) is a protein that is expressed in different types of cancer and
seems to be involved in the process of the tumour cells’ escape from the immune
system surveillance (immunoescape).
Aim: The aim of this study was to evaluate the clinical significance of RCAS1
immunohistochemical expression in non small cell lung cancer (NSCLC).
Methods: Tissue microarrays of tumor specimens from 112 patients with newly
diagnosed primary NSCLC were constructed. The sections were stained with
monoclonal antibodies against RCAS1, Ki-67 and CD3 using immunohistochemistry
and they were studied through computerized image analysis. Associations between
RCAS1, Ki-67 and CD3 expression and clinicopathological variables and survival
were analyzed. In all cases a p-value=0.05 was considered significant.
Results: RCAS1 expression was higher in grade III tumors, regardless of the
histological type, and in adenocarcinomas with lymphovascular invasion. A
positive correlation between RCAS1 and Ki-67 levels was observed. Moreover,
there was an inverse correlation of survival interval with RCAS1 and Ki-67
levels and patients with higher expression of RCAS1 or Ki-67 had a
significantly shorter survival than those with lower expression. There was also
an inverse correlation between RCAS1 expression and the percentage of CD3(+)
lympocytes inside the tumor. Finally, there was a positive correlation between
the percentage of CD3(+) lympocytes inside the tumor and the overall survival.
Conclusions: RCAS1 could be a useful immunohistochemical marker indicating
tumor aggressiveness and predicting poor prognosis for patients with NSCLC.
Lung cancer, RCAS1, Biomarker, Immunoescape, Prognosis
Number of references: